Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement - Candlesense
ARWR Partnership

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

(NASDAQ:ARWR) PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson’s Disease, and for other additional collaboration targets that will utilize Arrowhead’s proprietary Targeted RNAi Molecule (TRiMℱ) platform. Upon closing, Arrowhead will receive $200 million as an upf

Related Questions

How will the $200 million upfront payment affect Arrowhead’s cash runway and valuation? What development milestones and royalty structures are included in the Novartis deal, and how could they impact future earnings? How might this partnership shift Arrowhead’s competitive position in the RNAi space and influence market sentiment?
Find similar articles on Candlesense businesswire